Electra Therapeutics to Present ELA026 Clinical Data in Late-Breaking Oral Session at the 2024 European Hematology Association (EHA) Congress
![](https://electra-therapeutics.com/wp-content/uploads/2022/01/Group-6161@2x.png)
SOUTH SAN FRANCISCO, CA, June 3, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for a broad range of immunological diseases and cancer, announced today that clinical data for its lead drug candidate, ELA026, will be presented…
Electra Therapeutics Builds Leadership Team with Appointment of Dr. Graham Parry as Chief Scientific Officer and Dr. Kim-Hien Dao as Chief Medical Officer
![](https://electra-therapeutics.com/wp-content/uploads/2022/01/Group-6161@2x.png)
SOUTH SAN FRANCISCO, CA, June 3, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for a broad range of immunological diseases and cancer, announced today the appointment of…